Discovery of potent and selective covalent inhibitors of JNK

  • Chem Biol. 2012 Jan 27;19(1):140-54. doi: 10.1016/j.chembiol.2011.11.010.
Tinghu Zhang  1 ,  Francisco Inesta-Vaquera ,  Mario Niepel ,  Jianming Zhang ,  Scott B Ficarro ,  Thomas Machleidt ,  Ting Xie ,  Jarrod A Marto ,  NamDoo Kim ,  Taebo Sim ,  John D Laughlin ,  Hajeung Park ,  Philip V LoGrasso ,  Matt Patricelli ,  Tyzoon K Nomanbhoy ,  Peter K Sorger ,  Dario R Alessi ,  Nathanael S Gray
Affiliations
  • 1. Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Abstract

The mitogen-activated Kinases JNK1/2/3 are key Enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response. Here, we report the discovery of irreversible inhibitors of JNK1/2/3. We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resolution that show the compounds form covalent bonds with a conserved cysteine residue. JNK-IN-8 is a selective JNK Inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compound will be broadly useful as a pharmacological probe of JNK-dependent signal transduction. Potential lead compounds have also been identified for Kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.

Products